OR WAIT 15 SECS
Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.
The European Medicines Agency (EMA) has published its final 'Road map to 2015', a document that sets out the agency's key drivers for progress and strategic vision of operation for the next 5 years.
The European Medicines Agency (EMA) has published its final ‘Road map to 2015’, a document that sets out the agency’s key drivers for progress and strategic vision of operation for the next 5 years. The agency plans to prioritize public health needs, improving access to medicines, and optimizing the safe and rational use of medicines.
The road map builds on previous initiatives between 2005 and 2010 and proposes the following three priority areas:
The road map is a response to some of the key drivers for progress and change that are affecting the EMA. Since the road map to 2010, the EMA explained that its roles and responsibilities have expanded to cover more activities. For instance, new legislative provisions from the European Commission concerning falsified medicines and pharmacovigilance will have important consequences for the EU regulatory network and the EMA in particular given its coordinating role.
The EMA is also concerned by emerging public health challenges, such as demographic changes, antimicrobial resistance, climate change (particularly in view of the emergence of new diseases) and the rapid development of new technologies, including e-health). Additionally, there is a need to further develop the regulatory framework for new and emerging science, such as personalized medicine, nanotechnologies, regenerative medicines and synthetic biology, with respect to benefit/risk evaluation, potential safety issues, and ethical and environmental considerations.
The EMA has also noted the growing public demand for greater transparency, particularly with regards to the availability of up-to-date information on medicinal products, adverse drug reactions and clinical trials. However, the EMA also added that this will be a challenge. “Providing greater transparency will entail specific challenges, such as finding the right balance between making more information and documents available more quickly and protecting commercially confidential information, while also complying with personal-data legislation,” said the road map.
Detailed information about the implementation of the road map will be published in a separate document entitled From vision to reality. This document will provide information on the required prerequisites and the enablers (including operational and organisational aspects).
To optimize the implementation of the road map, the EMA will also complement its planning process by applying a multi-annual programming approach that will address aspects such as workload and resources forecasts and budget planning.
Related Content:PharmTech News